2023-08-18 08:51:27
Discovered in France and also studied in Belgium, this molecule targets a protein present in most tumor cells. The first results, although very preliminary, arouse great enthusiasm among specialists. Article reserved for subscribers By Elisa Doré (“Le Figaro”) Published on 08/18/2023 at 10:51 Reading time: 5 min
In recent decades, major medical advances have revolutionized the management of cancer: first, chemotherapies, of course, then immunotherapies or targeted therapies. Effective in many cases, these more or less traditional treatments are however often defeated by the deployment of resistance mechanisms in cancer cells. The consequences are then terrible: recurrences, inevitable, sometimes fatal.
In France, researchers from the National Center for Scientific Research (CNRS), however, may have unearthed a new lethal weapon: an antibody capable of defusing one of these main resistance mechanisms, shared by most cancer cells. Administered alone (we then speak of monotherapy), this new antibody, NP137, has stabilized or even reduced certain tumours.
This article is for subscribers only
Discover the rest, 1€ for 1 month (without commitment) With this offer, take advantage of: Unlimited access to all the articles, files and reports of the editorial staff The newspaper in digital version Reading comfort with limited
1692351331
#NP137 #mad #hope #universal #antibody #cancer
